AstraZeneca co-steers functional genomics initiative

This funding is part of the Human Functional Genomics Initiative, a programme that aims to advance our understanding of how genomic variation influences human physiology and how it changes over time and in disease. AstraZeneca is also contributing £7m to the programme.

The FGSL will enable collaboration with UK-based researchers by facilitating arrayed CRISPR genetic screening and will focus initially on studying non-cancerous diseases such as those affecting the immune, cardiovascular, neuronal and respiratory systems, with the potential to expand into other areas.

Screening campaigns will be performed as a collaboration, with MTI scientists carrying out the screens and providing expertise and technical support.

Dr Nicola McCarthy, Head of Research, Milner Therapeutics Institute, University of Cambridge said: “We are very excited to be part of this initiative. The award from the MRC has enabled the purchase of expensive equipment, including automation robotics, needed to run arrayed CRISPR screens at scale.

“In addition, funds provided by AstraZeneca, the MTI and MRC will mean that UK-wide academics can apply to collaborate with the FGSL in the knowledge that the costs of their screens will be supported, enabling democratised access to this opportunity.”

Professor Patrick Chinnery, Executive Chair, MRC, added: “This is an exciting time for UK functional genomics research. With MRC’s support the convergence of recent advances in gene-editing technology, artificial intelligence, and other technologies will allow us to answer research questions in ways that would have previously been impossible.

“The Human Functional Genomics Initiative is key to advancing the UKRI’s strategic priority to securing better health, ageing, and wellbeing.”